FINWIRES · TerminalLIVE
FINWIRES

$MRNA

48 stories mentioning MRNAUpdated 17d ago

Every FINWIRES story that references MRNA, newest first.

Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was little changed.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas cut its price target to $146 from $185, following the company's Q1 results late last week.Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 3.7%.Sonida Senior Living (SNDA) shares fell 3.3% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered into a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3%.

$ERAS$MRNA$SNDA$ZTS
Sectors

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Healthcare stocks were mixed Monday afternoon with the NYSE Healthcare Index rising 0.2% and the State Street Healthcare Select Sector SPDR ETF (XLV) little changed, paring earlier losses.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 2.2%.Sonida Senior Living (SNDA) shares fell 3.6% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3.3%, and Merck added 1.2%.

$ERAS$MRK$MRNA$SNDA
Research

Research Alert: CFRA Keeps Hold View On Shares Of Moderna; Shares +16% Amid Andes Outbreak

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MRNA shares rose over 16% in five days following an Andes virus (rare hantavirus strain) outbreak on cruise ship MV Hondius. The vessel, carrying ~150 passengers from 23 countries, departed Argentina on April 1 and docked in the Canary Islands on May 10 with six confirmed cases, two probable cases, and three deaths. While no hantavirus vaccine currently exists, mRNA technology offers advantages including rapid development, strain adaptability, and stronger immune response versus traditional vaccines. Moderna is developing an mRNA hantavirus vaccine with Korea University, though the program remains in early preclinical stages (animal studies only), suggesting substantial time is needed despite current market enthusiasm. Health officials assess the pandemic risk as low given the virus requires close, prolonged contact for transmission. The Andes virus is the only known hantavirus strain to spread person-to-person. We raise our target to $58 from $48 based on NPV analysis, maintain our 2026 LPS at -$7.95, and keep 2027 LPS at -$4.82.

$MRNA
Wire

Top Midday Stories: Moderna Working on Hantavirus Vaccine, Shares Rise; Blackstone, Halliburton to Invest Combined $1 Billion in VoltaGrid

The three major US stock indexes were up slightly in late-morning trading Monday after President Donald Trump said Sunday on Truth Social that he has rejected Iran's latest proposal to end the war.In company news, Moderna (MRNA) said it has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said, citing the company. Moderna shares were up 4.9% around midday.Blackstone (BX) and Halliburton (HAL) will invest a combined $1 billion into energy startup VoltaGrid in a deal that values the company at over $10 billion, Bloomberg reported Monday, citing people familiar with the matter. Separately, Blackstone agreed to acquire a majority stake in Greek online marketplace Skroutz from CVC Capital Partners, Bloomberg reported Monday. Financial terms of the deal were not disclosed, though people familiar with the matter reportedly told Bloomberg it values Skroutz at 635 million euros. Lastly, Blackstone Real Estate Debt Strategies has launched a lending platform to provide capital and flexibility to US homebuilders, the company said Monday. Blackstone shares were down 1.0%, while Halliburton shares were up 0.6%.Cerebras Systems is planning to increase the size and price of its initial public offering, the company said in a regulatory filing. Cerebras plans to raise its IPO price to a range of $150 to $160 per share from $115 to $125 per share and increase the number of shares marketed to 30 million from 28 million.Apollo Global Management (APO) said Monday its managed funds signed definitive agreements to buy Emerald Holding (EEX) and Questex to form a combined business events platform. The company will pay $5.03 per share to acquire Emerald, assigning the target company an expected value of about $1.50 billion, the company said. Separately, Apollo is in talks to sell its MidCap Financial Investment (MFIC) business development company, The Wall Street Journal reported Sunday, citing people familiar with the matter. Apollo values the business at around $3 billion, the report said, citing the sources. Apollo shares were down 0.8%, while Emerald shares were up 9.3% and MidCap shares were down 2.6%.FS KKR Capital (FSK) reported a Q1 loss Monday of $1.57 per diluted share. Total Q1 investment income was $304 million down from $400 million a year ago and below the FactSet consensus analyst estimate of $316.8 million. The company said Monday that KKR's (KKR) KKR Alternative Assets unit will launch a tender offer to buy up to $150 million of FS KKR Capital's shares at $11 each. The offering will begin Tuesday and is expected to expire on June 9, the company said. KKR Alternative Assets agreed to buy $150 million in newly issued shares of cumulative convertible perpetual preferred stock, FS KKR Capital said Sunday. FS KKR shares were up 0.5%, while KKR shares were down 2.8%.Alphabet (GOOG, GOOGL) on Monday filed a preliminary prospectus supplement with the SEC for a multi-tranche yen-denominated bond offering targeting qualified institutional investors in Japan. The offering consists of five series of notes with varying maturities and interest rates, with all payments to be made in Japanese yen, the filing said. Alphabet's Class C and Class A shares were down 1.8% and 1.9%, respectively.Walt Disney's (DIS) ABC network has been the victim of "sustained, coordinated" censorship by the Trump administration, Federal Communications Commissioner Anna Gomez said in a letter to Disney Chief Executive Josh D'Amaro, The Wall Street Journal reported Monday, citing the letter, which it viewed. Disney shares were down 2.0%.Price: $54.87, Change: $+0.52, Percent Change: +0.95%

$APO$BX$DIS$EEX$FSK$GOOG$GOOGL$HAL$KKR$MFIC$MRNA
Sectors

Sector Update: Healthcare Stocks Rise Premarket Monday

Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Moderna (MRNA) stock was up more than 8% after the company, according to Bloomberg, said it has been working on early stage vaccines targeting hantaviruses.Liquidia (LQDA) shares were up more than 3% after the company said it swung to Q1 earnings as revenue rose during the period.Zai Lab (ZLAB) received the US Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas, the company said. Zai Lab stock was up nearly 4% pre-bell.

$IBB$LQDA$MRNA$XLV$ZLAB
Commodities

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday as Trump Rejects Reported Iran Proposal

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.03% higher in Monday's premarket activity as US President Donald Trump rejected Iran's reported resolution offer.US stock futures were mixed, with S&P 500 Index futures down 0.1%, Dow Jones Industrial Average futures slipping 0.2%, and Nasdaq futures gaining 0.03% before the start of regular trading.The existing home sales data for April will be released at 10 am ET.In premarket activity, bitcoin was down by 0.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.1% higher, Ether ETF (EETH) advanced 0.9%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 2.8%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.4%, and the iShares US Technology ETF (IYW) was 0.5% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 0.6%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 2.6%, while the iShares Semiconductor ETF (SOXX) rose by 0.9%.Monday.com (MNDY) shares were up more than 24% in premarket activity after the company reported higher Q1 adjusted earnings and revenue.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%, the Vanguard Health Care Index Fund (VHT) retreated by 0.2%, while the iShares US Healthcare ETF (IYH) slipped 0.7%. The iShares Biotechnology ETF (IBB) was flat.Moderna (MRNA) stock rose over 9% premarket after Bloomberg reported the company has been working on early-stage vaccines targeting hantaviruses.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated by 0.01%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.01%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% lower.ORIX (IX) shares were up more than 8% pre-bell after the company reported higher fiscal 2026 earnings and revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.2%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 0.04%. The iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.3%. The VanEck Retail ETF (RTH) was down 0.4%, while the State Street SPDR S&P Retail ETF (XRT) retreated by 0.3%.United Parks & Resorts (PRKS) shares were down more than 3% pre-bell after the company reported a wider Q1 loss and lower revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated by 0.2%, while the Vanguard Industrials Index Fund (VIS) was down 0.1%, and the iShares US Industrials ETF (IYJ) was inactive.Grupo Aeroportuario del Pacifico (PAC) stock was down more than 1% before the opening bell. The company said it had started the process for the potential establishment of a trust for the issuance of energy and infrastructure investment trust certificates, with a view to subscribing to a minority equity stake in the 12 Mexican airport concessionaires that Grupo Aeroportuario operates.EnergyThe iShares US Energy ETF (IYE) rose 1.8%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.3%.Cameco (CCJ) stock was down more than 1% before Monday's opening bell after the company said that flooding in northern Saskatchewan collapsed the Smoothstone River Bridge, disrupting a key supply route to its McArthur River mine and Key Lake mill.CommoditiesFront-month US West Texas Intermediate crude oil rose 2.6% to $97.91 per barrel on the New York Mercantile Exchange. Natural gas was up 2.5% at $2.83 per 1 million British Thermal Units. The United States Oil Fund (USO) advanced 3.9%, while the United States Natural Gas Fund (UNG) was 3.3% higher.Gold futures for May fell by 1% to $4,683.40 an ounce on the Comex. Silver futures advanced by 1.2% to $81.81 an ounce. SPDR Gold Shares (GLD) was 1.1% lower, and the iShares Silver Trust (SLV) rose by 0.6%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CCJ$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IX$IYE$IYH$IYJ$IYK$IYW$MNDY$MRNA$PAC$PMR$PRKS$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare

Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Moderna (MRNA) stock was up more than 8% after the company, as per Bloomberg, said it has been working on early-stage vaccines targeting hantaviruses.

$MRNA
Wire

Moderna Shares Jump 8% After Company Flags Early Hantavirus Vaccine Work

Moderna (MRNA) shares rose over 7% in Monday's premarket after the company, as per Bloomberg, said it has been working on early-stage vaccines targeting hantaviruses.The vaccine maker said its research is still at an early stage and had begun before recent infections were reported aboard the Dutch-flagged Hondius, according to Bloomberg. The work is being carried out with the U.S. Army Medical Research Institute of Infectious Diseases and the Korea University College of Medicine, the report said.Moderna said its broader strategy includes preparing for emerging health threats using its mRNA platform, which can be adapted more quickly than conventional vaccine technologies, the report added.Price: $58.43, Change: $+4.08, Percent Change: +7.51%

$MRNA
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.

$AMGN$LLY$MRNA$VNDA
Wire

Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says

Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital said in a Friday note.According to the note, Moderna's Q1 results were driven by a stronger-than-expected COVID franchise, largely supported by international revenue recognition, while management reaffirmed its full-year outlook across revenue, R&D, SG&A, and capital expenditures.RBC highlighted ongoing momentum in Moderna's infectious disease pipeline, including upcoming flu vaccine regulatory milestones, progress on a flu-COVID combination shot, and advancement of its norovirus program, with data expected later this year depending on case accruals.On oncology, RBC noted upcoming catalysts for Moderna, including potential Phase III adjuvant melanoma data, updated Phase II results at ASCO, and a new pivotal early-stage non-small cell lung cancer study using its cancer vaccine platform.RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35.Shares of Moderna were up over 4% in Monday trading.Price: $47.57, Change: $+2.20, Percent Change: +4.85%

$MRNA
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Moderna, Inc. After Q1 Earnings

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After reviewing Q1 results, we up our target to $48 from $39, based on our NPV analysis. We widen our 2026 LPS view to -$7.95 from -$7.16 and keep our 2027 LPS view at -$4.82. MRNA reported a strong Q1, exceeding revenue expectations and demonstrating significant Y/Y growth. During the analyst call, management highlighted key regulatory approvals in Europe for its respiratory vaccine portfolio and oncology pipeline advancements, which we find encouraging. Despite a GAAP net loss widened by a one-time litigation settlement, underlying financial discipline and cost reduction efforts are noteworthy. Yet, revenue guidance for Q2 is relatively low at $50M-$100M (CFRA: $92M), which points to a 65%-30% Y/Y deceleration (CFRA: 35%) but also signals a significant swing Q/Q after the company recorded $153M in sales in Q1. While we think the progress in the oncology pipeline with the partnership with Merck & Co. (MRK 112 ****) is promising and progressing well, we continue to view MRNA as a wait and see story.

$MRNA
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Friday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.4%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 1.4%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 4.9%.Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said. Lilly shares rose 3.1%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.9%.

$AMGN$LLY$MRNA$NVO
Sectors

Sector Update: Health Care Stocks Softer Friday Afternoon

Health care stocks fell Friday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 2.9%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 5.6%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.2%.

$AMGN$MRNA$NVO
Wire

Morgan Stanley Raises Moderna Price Target to $33 From $30

Moderna (MRNA) has an average rating of Hold and mean price target of $45.21, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $44.92, Change: $-1.02, Percent Change: -2.22%

$MRNA
Sectors

Sector Update: Health Care

Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index fractionally higher and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) shed 0.8%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook on Friday and reported better-than-expected Q1 results amid higher COVID vaccine sales. Its shares still declined 2.7%.

$MRNA
US Markets

Moderna Maintains 2026 Revenue Growth Outlook as First-Quarter Results Beat Estimates

Moderna (MRNA) affirmed its 2026 revenue growth outlook on Friday and reported better-than-expected first-quarter results amid higher COVID vaccine sales.The company continues to expect full-year revenue to grow 10% on an annual basis. Analysts in a FactSet survey are projecting 2026 revenue of about $2.1 billion.For the quarter ended March 31, revenue rose to $389 million from $108 million a year earlier, while analysts expected $236.4 million. Net product sales surged to $352 million from $86 million amid higher COVID vaccine sales, boosted by deliveries under long-term strategic partnerships with government entities in international markets.Moderna posted a quarterly net loss of $3.40 per share, compared with a loss of $2.52 per share a year earlier. The Street's expectation was for a loss of $4.43 per share."The Moderna team delivered a great start to the year, driving significant revenue growth and substantial cost reductions building on actions taken in 2025," Chief Executive Stephane Bancel said in a statement. The company expects several additional approvals around the world this year, including for its seasonal flu vaccine, Bancel said.The company's stock was down 2.7% in Friday trade. It's up about 50% so far this year.The full-year revenue growth outlook incorporates potential future declines in COVID vaccination rates, offset by increased penetration of the company's COVID-19 vaccine mNEXSPIKE and revenue from its long-term strategic partnerships, Chief Financial Officer Jamey Mock said during an earnings call, according to a FactSet transcript.Moderna does not anticipate any material impact from the Middle East conflict on its 2026 outlook, Mock said.Price: $44.52, Change: $-1.42, Percent Change: -3.09%

$MRNA
Commodities

Exchange-Traded Funds Higher, Equity Futures Mixed Amid Continued Earnings Results

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively traded Invesco QQQ Trust (QQQ) gained 0.1% in Friday's premarket activity, as earnings reports continued to pour in.US stock futures were mixed, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average futures gaining 0.3%, and Nasdaq futures slipping by 0.2% before the start of regular trading.The S&P Global US manufacturing purchasing managers index for April will be released at 9:45 am ET, followed by the ISM Manufacturing Index for April at 10 am ET.The weekly Baker Hughes domestic oil-and-gas rig count posts at 1 pm ET.In premarket action, bitcoin was up by 1.4%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.3% higher, Ether ETF (EETH) advanced 2.1%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.6%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.4% and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was flat. The iShares US Consumer Staples ETF (IYK) was also flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.1%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was 0.5% higher.Estee Lauder (EL) shares were up more than 11% pre-bell after the company reported higher fiscal Q3 earnings and said it expects to eliminate between 9,000 and 10,000 positions as part of a revised profit recovery program.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.4%, the Vanguard Health Care Index Fund (VHT) was up 1.2%, while the iShares US Healthcare ETF (IYH) was inactive. The iShares Biotechnology ETF (IBB) was flat.Moderna (MRNA) stock was up more than 3% premarket after the company reported a narrower-than-expected net loss and higher revenue.EnergyThe iShares US Energy ETF (IYE) was down 0.1%, while the State Street Energy Select Sector SPDR ETF (XLE) was 0.4% lower.Imperial Oil (IMO) stock was down more than 2% before Friday's opening bell after the company reported lower Q1 net income and revenue.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.4%. Direxion Daily Financial Bull 3X Shares (FAS) was up 1.3%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 1.1% lower.Aon (AON) shares were up 3% pre-bell after the company reported higher Q1 adjusted earnings and revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.4%, while the Vanguard Industrials Index Fund (VIS) gained 0.4% and the iShares US Industrials ETF (IYJ) was inactive.Gates Industrial (GTES) stock was up more than 3% before the opening bell after Timken (TKR) agreed to sell the assets of its belts business to Gates.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.3%, and the iShares US Technology ETF (IYW) was 0.6% higher, while the iShares Expanded Tech Sector ETF (IGM) was down 0.03%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined by 0.4%, while the iShares Semiconductor ETF (SOXX) fell by 0.8%.Apple (AAPL) shares were up about 3% in premarket activity after the iPhone maker's fiscal Q2 results topped market estimates.CommoditiesFront-month US West Texas Intermediate crude oil fell by 2.6% to $102.31 per barrel on the New York Mercantile Exchange. Natural gas gained by 0.3% to $2.78 per 1 million British Thermal Units. The United States Oil Fund (USO) decreased by 2%, while the United States Natural Gas Fund (UNG) was 0.8% higher.Gold futures for May were down by 0.5% to $4,607.80 an ounce on the Comex. Silver futures added 1.5% to $75.31 an ounce. SPDR Gold Shares (GLD) was 0.5% lower, and the iShares Silver Trust (SLV) gained by 0.8%.

Dow JonesNasdaq CompositeS&P 500$AAPL$AON$BETH$BITO$EEM$EETH$EL$EXI$FAS$FAZ$GLD$GTES$IBB$IGM$IGV$IMO$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$MRNA$PMR$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Health Care Stocks Advance Pre-Bell Friday

Health care stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.2%.Novo Nordisk (NVO) shares were up more than 2% after the company said it has rebranded its oral semaglutide medication for type 2 diabetes, formerly known as Rybelsus, as Ozempic.Veeva Systems (VEEV) is set to join the S&P 500 on May 7, to replace Coterra Energy (CTRA), S&P Dow Jones Indices said. Shares of Veeva Systems were up more than 11% premarket.Moderna (MRNA) stock was up more than 2% after the company reported a narrower-than-expected Q1 net loss.

$CTRA$IBB$MRNA$NVO$VEEV$XLV
Research

Research Alert: Mrna Q1 Beats Estimates Despite Litigation Charge, Pipeline Advances

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Moderna's Q1 2026 revenue tripled to $389M, beating the consensus view by $154M, due to COVID-19 vaccine deliveries under international partnerships. Net loss widened to $(3.40) per share from $(2.52) prior year, though beat consensus by $0.48, primarily due to a $0.9B litigation settlement charge that added $(2.22) to EPS. We view the strong revenue performance and international expansion as positive, with international markets contributing 80% of revenue and completion of the first U.K. partnership shipment. Management maintained the 2026 guidance for up to 10% revenue growth with 50/50 U.S./international split. We believe regulatory milestones including European approval of combination vaccines and pipeline advancement demonstrate execution on its diversification strategy. Key upcoming catalysts include Phase 3 melanoma results, norovirus efficacy data, and the August PDUFA date for seasonal flu vaccine mRNA-1010.

$MRNA
US Markets

Stocks Mostly Up Pre-Bell as Investors Await More Corporate Earnings

The benchmark US stock measures were mostly pointing higher before the open Friday as investors await the week's final round of corporate earnings and track ongoing Middle East tensions, with no apparent signs of progress toward a peace deal between Washington and Tehran.The S&P 500 rose 0.1% and the Dow Jones Industrial Average added 0.2% in premarket activity, while the Nasdaq was off 0.1%. The indexes finished Thursday's trading session in the green, with the S&P 500 and Nasdaq logging new closing highs.Oil giants Exxon Mobil (XOM) and Chevron (CVX) are scheduled to release their latest quarterly results before the bell, along with Colgate-Palmolive (CL), Estee Lauder (EL), Moderna (MRNA), Magna International (MGA) and Newell Brands (NWL).Shares of Apple (AAPL) advanced 2.8% pre-bell as the iPhone maker's fiscal second-quarter results topped market estimates. Reddit (RDDT) climbed 16% after the social media platform recorded better-than-expected first-quarter results and issued an upbeat revenue outlook for the ongoing three-month period at the midpoint. Nvidia (NVDA) rebounded 0.4% following a 4.6% decline at the close of Thursday.President Donald Trump told reporters at the White House on Thursday that the US will maintain its naval blockade of Iranian ports, according to Bloomberg News. "Their economy is crashing, the blockade is incredible," Trump reportedly said. "So we'll see how long they hold out."Iran's new supreme leader, Mojtaba Khamenei, reportedly said Thursday that Iran will defend its nuclear and missile capabilities.West Texas Intermediate crude oil inclined 0.3% to $105.43 a barrel before the opening bell, while Brent increased 0.9% to $111.37.US economic growth fell short of Wall Street's expectations in the first quarter as spending slowed amid inflationary pressures, government data showed Thursday.Separate official data showed that inflation, as measured by the personal consumption expenditure price index, accelerated in March to the fastest pace since mid-2022 as the Middle East conflict sent energy prices soaring.Treasury yields were down in premarket action, with the two-year rate nudging 0.1 basis point lower to 3.88% and the 10-year rate decreasing 0.8 basis point to 4.38%.Friday's economic calendar has the final Purchasing Managers' manufacturing index for April at 9:45 am ET, followed by the Institute for Supply Management's manufacturing index for the same month at 10 am. The weekly Baker Hughes oil-and-gas rig count posts at 1 pm.Gold fell 1.1% to $4,578 per troy ounce, while bitcoin rose 1.1% to $77,248.

Dow JonesNasdaq CompositeS&P 500$AAPL$CL$CVX$EL$MGA$MRNA$NVDA$NWL$RDDT$XOM

Showing 21-40 of 48

Track with the FINWIRES app suite

FolioX
FolioX
Track MRNA in your portfolio
WheelAI
WheelAI
Analyze MRNA options with the wheel strategy
StockInsider
StockInsider
See market sentiment on MRNA